Show simple item record

Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia

dc.contributor.authorAyash, Lois J.en_US
dc.contributor.authorRatanatharathorn, Voraviten_US
dc.contributor.authorBraun, Thomasen_US
dc.contributor.authorSilver, Samuel M.en_US
dc.contributor.authorReynolds, Christopher M.en_US
dc.contributor.authorUberti, Joseph P.en_US
dc.date.accessioned2007-09-20T17:56:25Z
dc.date.available2008-04-03T18:45:17Zen_US
dc.date.issued2007-01en_US
dc.identifier.citationAyash, Lois J.; Ratanatharathorn, Voravit; Braun, Thomas; Silver, Samuel M.; Reynolds, Christopher M.; Uberti, Joseph P. (2007). "Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia." American Journal of Hematology 82(1): 6-14. <http://hdl.handle.net/2027.42/55885>en_US
dc.identifier.issn0361-8609en_US
dc.identifier.issn1096-8652en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/55885
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16986128&dopt=citationen_US
dc.description.abstractLimited data are available for adults undergoing unrelated donor (URD) BMT for AML using chemotherapy-only preparative regimens. Previous studies incorporated irradiation, included adults and children, and excluded secondary leukemia. Herein we report long-term outcomes for adults with poor-prognostic AML receiving a novel regimen of busulfan (16 mg/kg), cytarabine (8,000 mg/m 2 ), and cyclophosphamide (120 mg/kg) (BAC), followed by URD BMT. From June 1995 through October 2001, 45 adults were enrolled. Adverse features included unfavorable cytogenetics (49%), secondary AML (47%), leukemia at transplant (42%), and extramedullary disease (16%). At time of BMT, 23 were in remission (12 CR1) while 22 had leukemia. Four (9%) died early. Acute and chronic GVHD rates were 44 and 67%, respectively. Seventeen (38%) were disease-free 52 months post-BMT; 13 were leukemia-free (eight CR1) at transplant. Eleven relapsed. Three-year DFS and OS were 42 and 46%, respectively. DFS and OS were longer, and relapses less, for those in CR at time of BMT. Secondary leukemia, cytogenetics, cell dose, and GVHD did not influence outcome. In poor-risk AML, BAC provided cytoreduction comparable to reported TBI-containing regimens, when administered for URD BMT. With decreasing treatment-related mortality, it is justified to proceed early to URD BMT for patients with poor prognostic features. Am. J. Hematol., 2006. © 2006 Wiley-Liss, Inc.en_US
dc.format.extent145865 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherCancer Research, Oncology and Pathologyen_US
dc.titleUnrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemiaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan ; Karmanos Cancer Institute, 4100 John R, 4HWCRC, Detroit, MI 48201en_US
dc.contributor.affiliationumDepartment of Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Biostatistics, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.identifier.pmid16986128en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/55885/1/20759_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/ajh.20759en_US
dc.identifier.sourceAmerican Journal of Hematologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Accessibility: If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.